GENFLOW BIOSCIENCES PLC (WQ5) - Total Liabilities
Based on the latest financial reports, GENFLOW BIOSCIENCES PLC (WQ5) has total liabilities worth €771.38K EUR (≈ $901.83K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GENFLOW BIOSCIENCES PLC cash conversion from operations to assess how effectively this company generates cash.
GENFLOW BIOSCIENCES PLC - Total Liabilities Trend (2021–2024)
This chart illustrates how GENFLOW BIOSCIENCES PLC's total liabilities have evolved over time, based on quarterly financial data. See GENFLOW BIOSCIENCES PLC shareholders equity for net asset value and shareholders' equity analysis.
GENFLOW BIOSCIENCES PLC Competitors by Total Liabilities
The table below lists competitors of GENFLOW BIOSCIENCES PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Weizmann Limited
NSE:WEIZMANIND
|
India | Rs286.18 Million |
|
Kore Mining Ltd
V:KORE
|
Canada | CA$3.25 Million |
|
Energys Group Limited Ordinary Shares
NASDAQ:ENGS
|
USA | $10.36 Million |
|
NextCell Pharma AB
ST:NXTCL
|
Sweden | Skr10.34 Million |
|
BTC Health Ltd
AU:BTC
|
Australia | AU$248.95K |
|
Triton Holding Public Company Limited
BK:TRITN
|
Thailand | ฿1.53 Billion |
|
Anoto Group AB
ST:ANOT
|
Sweden | Skr94.39 Million |
|
Savannah Goldfields Ltd
AU:SVG
|
Australia | AU$33.16 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down GENFLOW BIOSCIENCES PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see WQ5 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENFLOW BIOSCIENCES PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENFLOW BIOSCIENCES PLC (2021–2024)
The table below shows the annual total liabilities of GENFLOW BIOSCIENCES PLC from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €788.92K ≈ $922.33K |
+37.93% |
| 2023-12-31 | €571.96K ≈ $668.68K |
+127.88% |
| 2022-12-31 | €250.99K ≈ $293.43K |
+13.35% |
| 2021-12-31 | €221.43K ≈ $258.87K |
-- |
About GENFLOW BIOSCIENCES PLC
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducin… Read more